[Chronic Hepatitis B (CHB) Supported Studies Committee. Last updated in June 2023.]
•   Understanding the patient perspective on unmet need in CHB
•   Understanding subpopulations in CHB with greatest need for improved outcomes e.g. those at most risk from HCC
•   Understanding impact of reduced access to care on outcomes in underserved populations with CHB
•   Understanding low diagnosis rates in CHB, impact to outcomes and opportunities to improve
•   Understanding the impact of CHB on patient-important outcomes, including functional cure
•   Measuring value of functional cure versus viral suppression in CHB
•   Understanding the biological mechanisms that lead to functional cure, including heterogeneity of virological and immunological effects
•   Societal and cultural impacts on treatment decision making
•   HBsAg qualitative versus quantitative assessment in CHB – role in improving CHB management and outcomes

[Primary Biliary Cholangitis (PBC) Supported Studies Committee. Last updated in June 2023.]
• Implementing/assessing care pathways that deploy quality-of-life measures and/or symptom assessments into routine clinical care of patients with PBC
• Investigating the mechanism of disease of cholestatic pruritus: basic and clinical research into the interplay of biomarkers, for example bile acids and LPA/autotaxin
• Improving the capture of patient reported outcomes in national/international PBC registries, to increase the understanding of the severity, and quality of life impact, of symptoms of PBC

[Nucala ISS/SCS Committee. Last updated in June 2022.]
GSK call for research proposals of relevance to disease understanding and impact of mepolizumab in two disease areas:
• Severe eosinophilic asthma (SEA)
• Hypereosinophilic syndrome (HES)
Applications are invited in the following areas:
• Impact of mepolizumab on prevention of organ damage and disease progression
• Composite outcomes with real-world use of mepolizumab, such as remission
• Patient identification biomarkers of those at risk of worse long-term clinical outcomes
• Non-eosinophilic biological effects of interleukin 5 (IL-5)
• CNS assessment of mechanisms of mepolizumab in promoting “well-being”

[Daprodustat ISS/SCS Committee. Last updated in May 2022.]
• Clinical practices and behaviours related to the management of anemia of CKD
• Healthcare resource utilisation related to anemia of CKD
• Burden and impact of untreated anemia of CKD across different geographies or related to differential healthcare access, including underserved populations
• Novel technologies to improve patient care and/or the patient experience in the management of anemia of CKD
• Effectiveness of Daprodustat in subgroups of special interest Including patients not reaching Hb target, inflamed patients, diabetic patients, anephritic patients, home dialysis, peritoneal dialysis, transplant
• New indications (other than anemia of CKD), where Daprodustat could benefit patients